Finally, the treatment of prostate cancer cell lines with this cNDI in combination with the AR antagonist Enzalutamide (used in second line therapies) resulted in a synergistic interaction in AR-positive but not in AR-negative cell lines. The gene discussed is AR; the disease is prostate cancer.